Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients
Official title: Comparison Between Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo - a Randomized Controlled Trial
Status: Enrolling by invitation
Description:
Patients of non-segmental vitiligo, fulfilling the inclusion criteria will be selected from the OPD, dermatology department. It's an interventional study where Group A patient will be given NBUVB and Tab Apremilast 30 mg twice a day and Group B will receive NBUVB alone.
Phase: Phase 4.
What is being studied: combination product — Apremilast with NB-UVB; device — NB-UVB.
Who can take part: ages 18 Years to 70 Years, 30 participants planned.
Enrollment status: Invitation only. The study started 01 January 2025 and is expected to finish 30 March 2027.
Source: ClinicalTrials.gov, NCT06593197 (https://clinicaltrials.gov/study/NCT06593197).
Start date: January 01, 2025
Completion date: March 30, 2027
Organizer: Dow University of Health Sciences
Link: https://clinicaltrials.gov/study/NCT06593197
The registry does not list a contact for this study. Use the link above to reach the study record on ClinicalTrials.gov.
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- Does vitiligo increase the risk of skin cancer?
No, it does not. Despite common misconceptions, people with vitiligo are actually at a lower risk of developing skin cancer—including both nonmelanoma skin cancer (NMSC) and mal...
- How Vitiligo Changes with Age?
Vitiligo, a condition characterized by the loss of skin pigmentation, can affect individuals at any stage of life. While it often appears before the age of 20, its progression a...
- Isn't it just a cosmetic disorder?
Contrary to popular belief, vitiligo is not merely a cosmetic issue but a complex autoimmune disorder that affects the body’s largest organ—along with other vital systems—and is...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.